Cargando…

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer

Cancer immunotherapy including immune checkpoint inhibitors (ICI) has revolutionized non-small cell lung cancer (NSCLC) therapy. Recently, the microbiota status “before” initiation of ICI therapy has been emphasized as a predictive biomarker in patients undergoing ICI therapy. However, the microbiot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shoji, Fumihiro, Yamaguchi, Masafumi, Okamoto, Masaki, Takamori, Shinkichi, Yamazaki, Koji, Okamoto, Tatsuro, Maehara, Yoshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Molecular Biosciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638091/ https://www.ncbi.nlm.nih.gov/pubmed/36353732 http://dx.doi.org/10.3389/fmolb.2022.1040424

Ejemplares similares

Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study
por: Shoji, Fumihiro, et al.
Publicado: (2022)

Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression
por: Takada, Kazuki, et al.
Publicado: (2017)

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2022)

Glycan-related genes in human gut microbiota exhibit differential distribution and diversity in carbohydrate degradation and glycan synthesis
por: Takihara, Hayato, et al.
Publicado: (2023)

Effects of the Lipid Metabolites and the Gut Microbiota in ApoE(−/−) Mice on Atherosclerosis Co-Depression From the Microbiota-Gut-Brain Axis
por: Hu, Ke, et al.
Publicado: (2022)

Chronological analysis of the gut microbiome for efficacy of atezolizumab‐based immunotherapy in non‐small cell lung cancer: Protocol for a multicenter prospective observational study
por: Shoji, Fumihiro, et al.
Publicado: (2022)

Metabolic characteristics of programmed cell death‐ligand 1‐expressing lung cancer on (18)F‐fluorodeoxyglucose positron emission tomography/computed tomography
por: Takada, Kazuki, et al.
Publicado: (2017)

Prediction Correction Topic Evolution Research for Metabolic Pathways of the Gut Microbiota
por: Ning, Li, et al.
Publicado: (2020)

Genomic reconstruction of short-chain fatty acid production by the human gut microbiota
por: Frolova, Maria S., et al.
Publicado: (2022)

Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status
por: Matsubara, Taichi, et al.
Publicado: (2021)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
por: Matsubara, Taichi, et al.
Publicado: (2021)

Understanding the Holobiont: Crosstalk Between Gut Microbiota and Mitochondria During Long Exercise in Horse
por: Mach, Núria, et al.
Publicado: (2021)

Administration of Lactobacillus fermentum KBL375 Causes Taxonomic and Functional Changes in Gut Microbiota Leading to Improvement of Atopic Dermatitis
por: Kim, Woon-Ki, et al.
Publicado: (2019)

Exploring Gut Microbiota in Patients with Colorectal Disease Based on 16S rRNA Gene Amplicon and Shallow Metagenomic Sequencing
por: Liu, Yuanfeng, et al.
Publicado: (2021)

Interaction of gut microbiota with the tumor microenvironment: A new strategy for antitumor treatment and traditional Chinese medicine in colorectal cancer
por: Li, Tingting, et al.
Publicado: (2023)

Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient
por: Takamori, Shinkichi, et al.
Publicado: (2020)

The significant influence of having children on the postoperative prognosis of patients with nonsmall cell lung cancer: A propensity score‐matched analysis
por: Takamori, Shinkichi, et al.
Publicado: (2018)

Gut microbiota-dependent adaptor molecule recruits DNA methyltransferase to the TLR4 gene in colonic epithelial cells to suppress inflammatory reactions
por: Narabayashi, Hikari, et al.
Publicado: (2022)

Impact of the pretreatment prognostic nutritional index on the survival after first‐line immunotherapy in non‐small‐cell lung cancer patients
por: Oku, Yuka, et al.
Publicado: (2023)

Nanoparticle-based immunotherapy of pancreatic cancer
por: Noubissi Nzeteu, Gaetan Aime, et al.
Publicado: (2022)

Metagenomics-based systematic analysis reveals that gut microbiota Gd-IgA1-associated enzymes may play a key role in IgA nephropathy
por: Liang, Xiaolin, et al.
Publicado: (2022)

Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota
por: Chen, Fengwu, et al.
Publicado: (2022)

The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
por: Hunia, Jaromir, et al.
Publicado: (2022)

Is radical local therapy effective in postoperative recurrent EGFR ‐mutated non‐small cell lung cancer?
por: Takenaka, Tomoyoshi, et al.
Publicado: (2023)

Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer
por: Song, Jingjing, et al.
Publicado: (2020)

Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma
por: Cerqueira, Otto Luiz Dutra, et al.
Publicado: (2022)

Comprehensive Pan-Cancer Analysis of Senescence With Cancer Prognosis and Immunotherapy
por: Zhao, Qinfei, et al.
Publicado: (2022)

Regulation mechanism of ferroptosis and its research progress in tumor immunotherapy
por: Xu, Jing, et al.
Publicado: (2022)

The role of p53 in anti-tumor immunity and response to immunotherapy
por: Carlsen, Lindsey, et al.
Publicado: (2023)

Multimodal treatment for resectable epithelial type malignant pleural mesothelioma
por: Yoshino, Ichiro, et al.
Publicado: (2004)

Characterization of the Immune Cell Infiltration Landscape of Thyroid Cancer for Improved Immunotherapy
por: Gong, Jing, et al.
Publicado: (2021)

Role of TFRC as a Novel Prognostic Biomarker and in Immunotherapy for Pancreatic Carcinoma
por: Yang, Cheng, et al.
Publicado: (2022)

Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis
por: Ye, Yingquan, et al.
Publicado: (2022)

Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy
por: Robilotti, Elizabeth, et al.
Publicado: (2023)

Full Spectrum Flow Cytometry as a Powerful Technology for Cancer Immunotherapy Research
por: Bonilla, Diana L., et al.
Publicado: (2021)

An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma
por: Liu, Long, et al.
Publicado: (2021)

A Pan-Cancer Analysis of IRAK1 Expression and Their Association With Immunotherapy Response
por: Liu, Mengmeng, et al.
Publicado: (2022)

A novel cuproptosis-related prognostic signature and potential value in HCC immunotherapy
por: Wang, Xiang-Xu, et al.
Publicado: (2022)

RelB is a potential molecular biomarker for immunotherapy in human pan-cancer
por: Wu, Jintao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7i7ip45ljm7kf3eienesqk43qv